Researchers have found a new way to reactivate fetal hemoglobin without the need for gene-editing therapy, according to a new study.

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, ...

The best healthcare stocks from Goldman Sachs' list that are also Quant Strong Buys have attractive valuations and forward ...

Discover how precision biotherapeutics can transform healthcare in India by personalizing treatments based on genetic and ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has not performed well for most of the year, and the company's latest quarterly update ...

This biotech has already made impressive contributions to medicine, and it could make more. But does that make it a buy?

In 2023, the U.S. Food and Drug Administration gave its approval to Casgevy, a commercial treatment that edits BCL11A genes ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Jayden Wilsey was the first person at Boston Children's Hospital to receive human gene therapy for sickle cell disease after federal approval in 2024.

Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria reductions and eGFR stabilization with povetacicept in patients with IgA ...